

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Nintedanib for treating idiopathic pulmonary fibrosis in people with a forced vital capacity above 80% [ID4062]

Draft scope

Draft remit/evaluation objective

To appraise the clinical and cost effectiveness of nintedanib within its marketing authorisation for treating idiopathic pulmonary fibrosis in people with a forced vital capacity above 80%.

Background

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease in which scarring (fibrosis) occurs. The cause of IPF is unknown although it is thought to be related to an abnormal immune response to an unknown cause. It is a difficult disease to diagnose and requires a multidisciplinary team. Most people with IPF experience symptoms of breathlessness, which may initially be only on exertion. Cough, with or without sputum, is a common symptom. Over time, these symptoms are associated with a decline in lung function, reduced quality of life and death.

The median survival for people with IPF in the UK is approximately 3-4 years from the time of diagnosis.^{1,2} However, about 20-30% of people with IPF survive for more than 5 years.^{1,2} The rate of disease progression can vary greatly. Prognosis is difficult to estimate at the time of diagnosis and may only become apparent after a period of careful follow-up.

The prevalence rate of IPF is about 50 per 100,000³ with an incidence of approximately 9 per 100,000 per year⁴, which equates to around 6000 new diagnoses each year in the UK.^{3,4} The incidence is higher in men than women, and increases with age (85% of diagnoses are made in people aged over 70 years).³ IPF co-exists with chronic obstructive pulmonary disease in around 8-15% of people.

The aim of treatment is to manage the symptoms and slow progression. NICE clinical guideline 163 on the diagnosis and management of suspected idiopathic pulmonary fibrosis recommends that best supportive care (including symptom relief, management of co-morbidities, withdrawal of therapies suspected to be ineffective or causing harm and end of life care) should be offered to people from diagnosis and be tailored according to disease severity, rate of progression and the person's preference. If pharmacological treatment is considered appropriate, the guideline recommends use of pirfenidone and nintedanib if a person's forced vital capacity (FVC) is between 50% and 80% of their expected value in line with recommendations in NICE technology appraisal guidance 504 and 379. Treatment with pirfenidone and nintedanib should be discontinued if there is evidence of disease progression (a decline in per cent predicted FVC of 10% or more within any 12 month period). Lung transplantation is an option if there are no contraindications.

The existing recommendations in NICE technology appraisal guidance 379 are optimised for a narrower population than covered by the marketing authorisation. Stakeholders have indicated that only recommending the use of these treatments to

Draft scope for the evaluation of nintedanib for treating idiopathic pulmonary fibrosis in people with a forced vital capacity above 80% [ID4062]

Issue Date: March 2022

Page 1 of 4

© National Institute for Health and Care Excellence 2022. All rights reserved.

when a person has a forced vital capacity (FVC) between 50% and 80% predicted does not reflect current clinical practice, and that there may be new information to warrant an update of the guidance.

The technology

Nintedanib (Ofev, Boehringer Ingelheim) has a UK marketing authorisation for treating idiopathic pulmonary fibrosis in adults. It is administered orally.

Intervention(s)	Nintedanib
Population(s)	Adults with idiopathic pulmonary fibrosis with a forced vital capacity above 80%
Comparators	Established clinical management without nintedanib
Outcomes	<p>The outcome measures to be considered include:</p> <ul style="list-style-type: none"> • pulmonary function parameters • physical function • exacerbation rate • progression-free survival • mortality • adverse effects of treatment • health-related quality of life.
Economic analysis	<p>The reference case stipulates that the cost effectiveness of treatments should be expressed in terms of incremental cost per quality-adjusted life year.</p> <p>The reference case stipulates that the time horizon for estimating clinical and cost effectiveness should be sufficiently long to reflect any differences in costs or outcomes between the technologies being compared.</p> <p>Costs will be considered from an NHS and Personal Social Services perspective.</p> <p>The availability of any commercial arrangements for the intervention, comparator and subsequent treatment technologies will be taken into account.</p>
Other considerations	<p>Guidance will only be issued in accordance with the marketing authorisation. Where the wording of the therapeutic indication does not include specific treatment combinations, guidance will be issued only in the context of the evidence that has underpinned the marketing authorisation granted by the regulator.</p>
Related NICE recommendations	Related Technology Appraisals:

	<p>'Nintedanib for treating idiopathic pulmonary fibrosis' (2016) NICE Technology appraisal guidance 379. Under review, anticipated date of publication TBC.</p> <p>'Pirfenidone for treating idiopathic pulmonary fibrosis' (2018). NICE Technology appraisal guidance 504. Under review, anticipated date of publication TBC.</p> <p>Related Guidelines:</p> <p>'COVID-19 rapid guideline: interstitial lung disease' (2020). NICE guideline 177.</p> <p>'Idiopathic pulmonary fibrosis in adults: diagnosis and management (2013). NICE guideline 163.</p> <p>Related Quality Standards:</p> <p>'Idiopathic pulmonary fibrosis in adults' (2015). NICE quality standard 79.</p>
<p>Related National Policy</p>	<p>The NHS Long Term Plan, 2019. NHS Long Term Plan</p> <p>Adult highly specialist respiratory services, chapter 4. NHS England (2018/2019) NHS manual for prescribed specialist services (2018/2019)</p>

Questions for consultation

Which treatments are considered to be established clinical management in the NHS for idiopathic pulmonary fibrosis with a forced vital capacity above 80%?

Is pirfenidone considered to be established clinical management in the NHS for idiopathic pulmonary fibrosis with a forced vital capacity above 80%?

Where do you consider nintedanib will fit into the existing care pathway for idiopathic pulmonary fibrosis?

Would nintedanib be a candidate for managed access?

Do you consider nintedanib to be innovative in its potential to make a significant and substantial impact on health-related benefits and how it might improve the way that current need is met (is this a 'step-change' in the management of the condition)?

Do you consider that the use of nintedanib can result in any potential substantial health-related benefits that are unlikely to be included in the QALY calculation?

Please identify the nature of the data which you understand to be available to enable the committee to take account of these benefits.

NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Please let us know if you think that the proposed remit and scope may need changing in order to meet these aims. In particular, please tell us if the proposed remit and scope:

- could exclude from full consideration any people protected by the equality legislation who fall within the patient population for which nintedanib is licensed;

- could lead to recommendations that have a different impact on people protected by the equality legislation than on the wider population, e.g. by making it more difficult in practice for a specific group to access the technology;
- could have any adverse impact on people with a particular disability or disabilities.

Please tell us what evidence should be obtained to enable the committee to identify and consider such impacts.

NICE intends to evaluate this technology through its Single Technology Appraisal process. We welcome comments on the appropriateness of appraising this topic through this process. (Information on NICE's health technology evaluation processes is available at <https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation>).

References

1. NHS. [Idiopathic pulmonary fibrosis](#). [online accessed March 2022]
2. Khor, Y et.al. (2020) Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review. *European Respiratory Review*. 29: 190158
3. British Lung Foundation (2016) [The battle for breath – the impact of lung disease in the UK](#). [online accessed March 2022]
4. Hutchinson, J (2015) Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. *European Respiratory Society*. 46: 795-806